- Home
- GYRE vs EBS Comparison
GYRE vs EBS Comparison
Compare GYRE & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GYRE | EBS |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.7M | 663.3M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | GYRE | EBS |
|---|---|---|
| Price | $8.01 | $11.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.00 | $15.00 |
| AVG Volume (30 Days) | 77.3K | ★ 960.3K |
| Earning Date | 03-16-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.04 | ★ 1.35 |
| Revenue | $107,265,000.00 | ★ $788,900,000.00 |
| Revenue This Year | $11.59 | N/A |
| Revenue Next Year | $26.31 | $15.21 |
| P/E Ratio | $205.16 | ★ $8.67 |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $6.11 | $4.02 |
| 52 Week High | $13.75 | $14.06 |
Technical Indicators
Market Signals| Indicator | GYRE | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 48.90 |
| Support Level | $7.78 | $11.53 |
| Resistance Level | $8.17 | $12.31 |
| Average True Range (ATR) | 0.30 | 0.70 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 57.17 | 44.03 |
Price Performance
Historical ComparisonAbout GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.